WO2021188404A1 - Formes à l'état solide d'otéséconazole et leur procédé de préparation - Google Patents

Formes à l'état solide d'otéséconazole et leur procédé de préparation Download PDF

Info

Publication number
WO2021188404A1
WO2021188404A1 PCT/US2021/022284 US2021022284W WO2021188404A1 WO 2021188404 A1 WO2021188404 A1 WO 2021188404A1 US 2021022284 W US2021022284 W US 2021022284W WO 2021188404 A1 WO2021188404 A1 WO 2021188404A1
Authority
WO
WIPO (PCT)
Prior art keywords
oteseconazole
crystalline
piperazine
theta
degrees
Prior art date
Application number
PCT/US2021/022284
Other languages
English (en)
Inventor
Luna Ben-Sahel KATSAV
Limor ADANI
Firas MASRI
Original Assignee
Assia Chemical Industries Ltd
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assia Chemical Industries Ltd, Teva Pharmaceuticals Usa, Inc. filed Critical Assia Chemical Industries Ltd
Publication of WO2021188404A1 publication Critical patent/WO2021188404A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present disclosure includes processes for preparing the above mentioned pharmaceutical compositions.
  • the processes include combining any one or a combination of the crystalline polymorph of Oteseconazole and/or crystalline Oteseconazole: Piperazine or the described solid state forms thereof with at least one pharmaceutically acceptable excipient.
  • the crystalline polymorph of Oteseconazole and/or crystalline Oteseconazole Piperazine as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorph of Oteseconazole and/or crystalline Oteseconazole: Piperazine may be used as medicaments, such as for the treatment of acute Vulvovaginal Candidiasis or Recurrent Vulvovaginal Candidiasis (RVVC) , or tinea pedis, onychomycosis, candidiasis, meningitis (e.g., cryptococcal meningitis), or mucormycosis.
  • RVVC Recurrent Vulvovaginal Candidiasis
  • the crystalline polymorph of Oteseconazole and crystalline Oteseconazole may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density.
  • Crystalline Form 01 of Oteseconazole may be further characterized by an X-ray powder diffraction pattern having peaks at 11.0, 12.8, 17.3, 17.7 and 26.7 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 14.9, 18.9, 21.5, 23.2 and 24.5 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • crystalline Form 01 of Oteseconazole is isolated.
  • the crystalline Oteseconazole Form 01 described herein may be substantially free of any other solid state forms of Oteseconazole.
  • crystalline Oteseconazole Form 01 according to any aspect or embodiment of the present invention contains about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% (w/w) of any other forms of Oteseconazole as measured, for example, by XRPD.
  • Oteseconazole Form 01 which comprises a sol vent/ anti solvent crystallization.
  • Oteseconazole Form 01 may be prepared by a solvent/anti solvent crystallisation wherein the solvent may be an alcohol, or an ester, wherein the alcohol amyl alcohol, isobutanol or cyclohexanol.
  • the ester is a C2-6 ester, more preferably ethyl formate, methyl formate, isobutyl acetate, or ethyl acetate.
  • the antisolvent may be used in an amount of about 2 to about 30 vol, about 5 to about 20 vol, or about 10 vol.
  • the alkane is cooled to a temperature of about 0°C to about 10°C, about 0 to about 5°C, or about 0°C to about 4°C, or about 2°C, optionally with stirring.
  • Crystalline Form PCC1 of Oteseconazole Piperazine may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 9.2, 12.2, 18.5, 22.5 and 23.5 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 2, and combinations thereof.
  • the present disclosure relates to crystalline Oteseconazole: Piperazine and a solid state form thereof.
  • the present disclosure also relates to pharmaceutical compositions including the solid state form of Oteseconazole: Piperazine.
  • the present disclosure provides the above described crystalline polymorphs of Oteseconazole and crystalline Oteseconazole: Piperazine for use in the preparation of pharmaceutical compositions comprising Oteseconazole and crystalline Oteseconazole: Piperazine and/or crystalline polymorphs thereof.
  • the present disclosure also encompasses the use of crystalline polymorphs of Oteseconazole and crystalline Oteseconazole: Piperazine of the present disclosure for the preparation of pharmaceutical compositions of crystalline polymorph Oteseconazole, crystalline Oteseconazole: Piperazine and/or crystalline polymorphs thereof.
  • the dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach can be increased by the addition of a disintegrant to the composition.
  • Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac- Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
  • alginic acid include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac- Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplas
  • the solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral.
  • the dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
  • Scanning parameters range: 2-40 degrees two-theta; scan mode: continuous scan; step size:
  • Oteseconazole can be prepared according to methods known from the literature, for example U.S. Patent No. 8,236,962.
  • Example 7 Preparation of crystalline Oteseconazole:piperazine Form PCC1 [00127] Oteseconazole (1 gram, 1.89 mmol) was added to THF (3 ml, 3 V) at 40°C, under stirring to give clear solution. The obtained hot clear solution was mechanically filtrated upon filter disk. Then, piperazine (0.5 eq., 0.945 mmol) was added to the stirred solution upon 40°C. The reaction mixture was stirred at 40°C for additional 10 minutes followed by cooling spontaneously to room temperature. Next, the clear mixture was cooled to 4°C and continues stirring upon this temperature, followed by addition of cold n-heptane (15ml, 15 V) and kept with stirring for minimum 2 hours at 4°C to give precipitant.
  • THF 3 ml, 3 V
  • piperazine 0.5 eq., 0.945 mmol

Abstract

La présente divulgation porte sur l'otéséconazole et des formes à l'état solide d'otéséconazole : La pipérazine, dans des modes de réalisation sous formes polymorphes cristallines d'otéséconazole et de l'otéséconazole cristallin : La pipérazine, des procédés de préparation correspondants, et des compositions pharmaceutiques associées.
PCT/US2021/022284 2020-03-19 2021-03-15 Formes à l'état solide d'otéséconazole et leur procédé de préparation WO2021188404A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062991635P 2020-03-19 2020-03-19
US62/991,635 2020-03-19
US202063010769P 2020-04-16 2020-04-16
US63/010,769 2020-04-16

Publications (1)

Publication Number Publication Date
WO2021188404A1 true WO2021188404A1 (fr) 2021-09-23

Family

ID=75302693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/022284 WO2021188404A1 (fr) 2020-03-19 2021-03-15 Formes à l'état solide d'otéséconazole et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2021188404A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236962B2 (en) 2010-04-24 2012-08-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2015143180A1 (fr) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique
WO2016149486A1 (fr) * 2015-03-19 2016-09-22 Viamet Pharmaceuticals, Inc. Composés antifongiques et procédés de fabrication
WO2017049080A1 (fr) * 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236962B2 (en) 2010-04-24 2012-08-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2015143180A1 (fr) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique
WO2016149486A1 (fr) * 2015-03-19 2016-09-22 Viamet Pharmaceuticals, Inc. Composés antifongiques et procédés de fabrication
US9840492B2 (en) 2015-03-19 2017-12-12 Viamet Pharmaceuticals, Inc. Antifungal compounds and processes for making
US10370353B2 (en) 2015-03-19 2019-08-06 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
US10414751B2 (en) 2015-03-19 2019-09-17 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
US10676459B2 (en) 2015-03-19 2020-06-09 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
WO2017049080A1 (fr) * 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems"
BRAND STEPHEN R. ET AL: "A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, vol. 218, no. 6, 1 June 2018 (2018-06-01), US, pages 624.e1 - 624.e9, XP055803442, ISSN: 0002-9378, DOI: 10.1016/j.ajog.2018.03.001 *
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 *

Similar Documents

Publication Publication Date Title
US20230183235A1 (en) Solid state forms of amg-510 and process for preparation thereof
US20210387952A1 (en) Solid state forms of daprodustat and process for preparation thereof
US20210292479A1 (en) Solid state forms of sugammadex sodium
US20230057197A1 (en) Solid state forms of mavacamten and process for preparation thereof
US20230167090A1 (en) Solid state forms of aprocitentan and process for preparation thereof
EP4352056A1 (fr) Formes à l'état solide de lanifibranor et leur procédé de préparation
US20230098234A1 (en) Solid state forms of mitapivat and process for preparation thereof
US20240010629A1 (en) Solid state form of lemborexant
WO2022177927A1 (fr) Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
US20220356165A1 (en) Solid state forms of roluperidone and salts thereof
EP4214212A1 (fr) Formes à l'état solide de sep-363856 et leur procédé de préparation
EP4034256A1 (fr) Formes à l'état solide de sels de lucérastat et leur procédé de préparation
WO2021188404A1 (fr) Formes à l'état solide d'otéséconazole et leur procédé de préparation
US20220220149A1 (en) Solid state forms of sage-217 and processes for preparation thereof
US11434202B2 (en) Crystalline polymorphs of Rivoceranib and Rivoceranib mesylate
US20230071463A1 (en) Solid state forms of avasopasem manganese and process for preparation thereof
EP4298088A1 (fr) Formes à l'état solide de tideglusib et leur procédé de préparation
WO2023199258A1 (fr) Formes à l'état solide de mavacamten et leur procédé de préparation
WO2021216628A1 (fr) Formes solides de trifarotène et leur procédé de préparation
WO2023158772A1 (fr) Formes à l'état solide de danicopan et procédé associé
WO2024069574A1 (fr) Formes à l'état solide de denifanstat
EP4271678A1 (fr) Formes solides de capivasertib et leur procédé de préparation
WO2024089582A1 (fr) Formes à l'état solide de sels de cilofexor
WO2024095127A1 (fr) Formes à l'état solide de tivozanib et leur procédé de préparation
WO2022225712A1 (fr) Formes à l'état solide de firibastat et leurs processus de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21715763

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31/01/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21715763

Country of ref document: EP

Kind code of ref document: A1